To improve future drug development efficiency in renal cell carcinoma (RCC), a disease‐
progression model was developed with longitudinal tumor size data from a phase III trial of …

The classical model for identification and clinical development of anticancer agents was
based on small molecules, which were often quite toxic. Early studies in small groups of …

Pavan Reddy, MD The pathophysiology of acute graft-versus-host disease (aGVHD) is
known to involve donor T cells responding to host histoincompatible allo-antigens presented …

BACKGROUND Use of progression‐free survival (PFS) as a clinical trial endpoint in first‐
line treatment of patients with metastatic urothelial carcinoma (UC) is attractive, but would be …

Recent advances in biotechnology have led to discoveries resulting in major improvements
in the therapy of refractory malignancies, although most advanced cancers remain …

Human tumor in vivo cancer models raised in immunodeficient mice, the so-called patient-
derived xenografts, are increasingly in use in preclinical development and evaluation of …

Objective An investment-making decision is a multifaceted process that requires the
investor's precision, punctuality, and timely decision. This process is influenced by future …

Most clinical trials with combination therapy fail. One of the reasons is that not enough
forethought is given to the interaction between the different agents, as well as the potential …

Umbrella and basket trials evaluate multiple experimental treatments, multiple diseases, or
both under a single trial infrastructure and protocol. There is a need to develop efficient …